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Medullary thyroid cancer (MTC) is a rare neuroendocrine neoplasm that accounts for approximately 5% of all thyroid
malignancies. The natural history of MTC is characterized by early lymph node and distant metastases, making complete surgical
cureoftenimpossible.Conventionalchemotherapyandexternalbeamradiationhavebeenlargelyineﬀectiveinalteringthenatural
historyofMTC.Therefore,thereisagreatneedtodevelopnoveltherapeuticstrategiestoaﬀectsymptomcontrolandreducetumor
burden in patients with widely disseminated disease. Here, we review several pathways which have been shown to be vital in MTC
tumorigenesis and focus on the pathways of interest for which targeted drug therapies are currently being developed.
Copyright © 2009 Scott N. Pinchot et al. This is an open access article distributed under the Creative Commons Attribution
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1.Introduction
Medullary carcinomas of the thyroid are neuroendocrine
neoplasms derived from the parafollicular cells, or C cells,
of the thyroid and account for nearly 5–10% of thyroid
malignancies [1]. In nearly all cases of medullary thyroid
cancer (MTC), the C cells secrete calcitonin, a speciﬁc and
highly sensitive biomarker whose measurement plays an
important role in the diagnosis and postoperative followup
of patients [2, 3]. Less common, MTC cells elaborate other
polypeptide hormones, including vasoactive intestinal pep-
tide (VIP), serotonin, somatostatin, and carcinoembryonic
antigen (CEA), the latter of which has been shown to
herald contralateral lymph node and distant metastases
[4].
The majority of MTCs are sporadic, but up to 25% of
MTC cases result from a germ-line activating mutation in
the rearranged during transfection (RET) proto-oncogene
[5, 6]. Hereditary MTCs occur in the setting of the multiple
endocrine neoplasia (MEN) syndrome type 2 (2A or 2B) or
as familial MTC (FMTC) without an associated MEN syn-
drome. In sporadic MTC, patients most commonly present
in the ﬁfth or sixth decade with a palpable cervical lymph
node or a solitary thyroid nodule. Fine needle aspiration
(FNA) biopsy of the mass and the presence of an elevated
serum calcitonin are diagnostic of MTC. Unlike sporadic
MTC, most patients with hereditary disease are identiﬁed by
genetic testing of at-risk family members for the germline
mutation of the RET gene. As such, hereditary MTC tends to
present at an earlier age than sporadic disease and is typically
multifocal and bilateral [1].
The management of MTC relies heavily on surgical
resection, consisting of total thyroidectomy and lymph
node dissection; however, recurrent disease develops in
approximately 50% of patients with MTC [7]. Similarly,
biochemical documentation of persistent or recurrent MTC
by serum calcitonin levels is often associated with unre-
sectable recurrence in distant locations, including lung and
liver [8]. Therefore, although MTC tends to be a slow-
growing tumor primarily treated with surgical resection, it
frequently metastasizes early in the disease course to the
liver and regional lymph nodes, precluding patients from a
curative resection. It is thus necessary to develop alternative
therapeutic strategies to control tumor growth, possibly
through manipulation of various cellular signaling pathways
[9].2 Journal of Oncology
Table 1: Targeted therapies currently in clinical trial development for MTC.
Drug Target Mechanism of action
Zactima (ZD6474) VEGFR, RET, EGFR (HER1) Tyrosine kinase inhibitor
XL184 VEGFR2, MET, RET Tyrosine kinase inhibitor
Imatinib (STI571) bcr-abl, PDGFR, C-KIT Tyrosine kinase inhibitor
Soraﬁnib (BAY-43-9006) BRAF, CRAF, VEGFR, RET, PDGFR Tyrosine kinase inhibitor
Sunitinib (SU11248) VEGFR, RET, PDGFR, C-KIT, CSF-1R, ﬂt3 Tyrosine kinase inhibitor
AMG-706 VEGFR1-3, PDGFR, C-KIT Tyrosine kinase inhibitor
Geﬁtinib EGFR (HER1) Tyrosine kinase inhibitor
Axitinib (AG-013736) VEGFR, PDGFR, C-KIT Tyrosine kinase inhibitor
Pazopanib (GW786034) VEGFR1-3, PDGFR, C-KIT Tyrosine kinase inhibitor
SAHA Notch1, TNF-α,I L - 1 - β, IL-6, IFN-γ HDAC inhibitor
Lithium GSK-3ß Unknown, suspected GSK3 inhibition, inositol depletion
2. MolecularPathogenesis andCytogenetics
Although MTC is rare, there has been considerable interest
in the molecular pathways that regulate MTC cellular
growth, diﬀerentiation, survival, and hormone expression.
We and others have previously shown that manipulation
of these pathways may be a potential therapeutic strategy
to control the growth and hormone production of NE
tumors like MTC [9–12]. With the application of current
molecular techniques, decades of research have begun to
elucidate a genetic model that contributes to MTC tumori-
genesis that includes three important processes: mutated
proto-oncogenes which result in altered receptor protein
production and concomitant accelerated tumor growth,
alterations in signal transduction pathways which regulate
the NE phenotype, and variations in tumor suppressor
genes that facilitate unregulated cell growth [13]. Although
a comprehensive review of all pathways which have been
studied is beyond the scope of this paper, we aim to focus
on new pathways of interest in MTC for which targeted drug
therapies are currently in development (Table 1).
3. Receptor Proteins
3.1. The RET Receptor Tyrosine Kinase (RTK). Activating
germline mutations in familial MTC involve the RET proto-
oncogene, which is mapped to chromosome 10q11.2 [1].
The RET gene encodes a 120-kDa transmembrane receptor
tyrosine kinase (RTK) that functions as a target for the
glial-derived neurotrophic factor (GDNF) family of growth
factors [14]. Mutations in the RET proto-oncogenes have
been implicated in nearly 95% of cases of hereditary
MTC associated with MEN types 2A and 2B and FMTC.
Interestingly, in hereditary MTC, recent data suggest that
speciﬁc germline RET mutations are associated with age-
speciﬁc penetrance of cancer development and lymph node
metastases [2, 15] .T h em o s tc o m m o nm u t a t i o ni nM E N
2A (codon 634) occurs in up to 80% of MEN 2 families
and nearly half of aﬀected children develop MTC by ages
5–10. The codon most frequently associated with MEN 2B
(codon 918) confers a signiﬁcantly higher risk of MTC, often
beginning in the ﬁrst 6 months of life. Patients assigned to
this highest risk category clearly beneﬁt from prophylactic
thyroidectomy in the ﬁrst year of life, if possible.
While MTC displays a slow-growth pattern and indolent
disease course, frequent metastases to the liver and regional
nodalbasinsplaguepatientswithhereditarydisease,preclud-
ing these patients from a curative resection. Clearly, there is
a great need for novel therapeutic and palliative strategies to
treat these patients with metastatic MTC.
Several small molecule RTK inhibitors have been devel-
oped against RET and show promising results both in vitro
and in vivo as emerging therapies for the treatment of MTC.
These molecules include ZD6474 (Vendetanib), SU11248
(sunitinib), BAY 43-9006(sorafenib), CEP-751 and CEP-701,
XL-880, XL-184, and RPI-1 [2, 16]. Much is known about
vandetanib, a low molecular weight tyrosine kinase inhibitor
that has demonstrated eﬀective inhibition of RTK in vitro
[17, 18]. Likewise, Carlomagno et al. [17] have shown that
vandetanib blocks in vivo phosphorylation and signaling
of the RET/MEN2B oncoprotein and prevents the growth
of two human cancer cell lines that carry spontaneous
RET rearrangements. Currently, promising data in patients
with MTC have led to vandetanib being assigned orphan
drug designation by the US Food and Drug Administration.
These data are based on studies in which vandetanib has
demonstrated clinical activity in a single-arm Phase II study
in patients with metastatic hereditary MTC [19]. In this
study, thirty patients (21 female; median age 50 years)
received initial treatment with vandetanib 300mg with a
median duration of treatment of 172 days. Based on site
investigator assessments, 20% (6/30) of patients experienced
a partial response (duration of response 59–260 days) and
another 30% (9/30) of patients experienced stable disease
at 24 weeks, yielding a disease control rate of 50% (15/30).
Similarly, in 19 patients, plasma calcitonin levels showed a
>50% decrease from baseline that was maintained for at least
6weeks.Basedontheseandotherdata,aninternational,ran-
domized, placebo-controlled Phase III study of vandetanib
monotherapy in metastatic MTC has been initiated and is
currently ongoing.
In addition to vandetanib, several other novel RTK
inhibitors are under investigation for treatment of RET-
dependent thyroid carcinomas. Recently, Kim et al. haveJournal of Oncology 3
shown that sorafenib, a multikinase inhibitor of RTK,
VEGFR, and BRAF kinase, inhibits proliferation of ATC
cell lines and inhibits tumor angiogenesis via induction of
endothelial apoptosis in an orthotopic anaplastic thyroid
carcinoma xenograft model in nude mice [20]. Similarly,
the orally administered multitarget tyrosine kinase inhibitor,
sunitinib, has been shown to be a novel potent inhibitor of
thyroidoncogenicRET/papillarythyroidcancerkinases[21].
Many of these agents which are earlier in the development
pipeline are capable of inhibiting RET at subnanomolar con-
centrations and hold signiﬁcant promise for the treatment
and palliation of hereditary MTC [2].
3.2. EGFR as a Therapeutic Target. Epidermal growth fac-
tor (EGF) is a 6-kDa polypeptide which has been dem-
onstrated to stimulate the proliferation of normal and
malignant thyroid cells and inhibit cellular diﬀerentiation
[22]. Overexpression of the EGF receptor (EGFR), a 170-
kDa transmembrane glycoprotein tyrosine kinase, has been
documented in various diﬀerentiated thyroid carcinomas
[23, 24] and is thought to be essential in thyroid carci-
noma proliferation and metastasis. Recently in a proteomics
study of MTCs expressing RET germ-line mutations, Gorla
and colleagues [25] demonstrated high-level expression of
minimally phosphorylated EGFR in two separate MTC cell
lines. These data, taken together with studies demonstrating
that geﬁtinib and erlotinib, well known EGFR inhibitors,
have resulted in objective tumor responses in patients with
EGFR-overexpressing tumors, suggest that EGFR inhibitors
might be beneﬁcial for therapy of refractory or metastatic
MTC. Interestingly, several of the novel RTK inhibitors—
vandetanib, sorafenib, and sunitinib, for example—appear
to be multitarget kinase inhibitors capable of nonspeciﬁc
inhibition of multiple critical signaling pathways critical
in MTC tumorigenesis. While vandetanib is currently in
phase II clinical trials to measure eﬃcacy and clinical
response in patients with hereditary MTC, the question of
whether the multitarget kinase inhibitors’ lack of receptor
speciﬁcity will be advantageous or disadvantageous remains
unanswered.
3.3. Angiogenesis Inhibitors. Many proteins appear to be
involved in the formation and maintenance of new blood
vessels which support primary tumor growth and metastatic
tumor deposits. One of these proteins, vascular endothelial
growth factor (VEGF), stimulates angiogenesis by attaching
to VEGF receptors on the endothelial cells, supporting
new vessel stability [26]. Interestingly, several recent studies
suggest that thyroid cancer cells demonstrate elevated levels
of VEGF compared to normal controls.
To date, several phase II clinical trials have been com-
pleted in MTC for single agent small molecules which target
the VEGF receptor. AG-013736 (Axitinib) is a potent small
molecule inhibitor of VEGF receptors 1 through 3 which has
been shown in a single arm multicenter trial to be associated
with an overall partial response rate of 20% in patients with
thyroid cancer of any histology that was resistant or not
appropriate for 131I. Among patients with MTC, nearly 20%
(2/11 patients) demonstrated radiographic partial responses
while almost half (5/11 patients) of all MTC patients
exhibited stabilization of disease. Therapy was well tolerated,
with reported side-eﬀects of fatigue, hypertension, and
proteinuria [27]. A similar phase II trial of the multikinase
inhibitor AMG-706 in MTC has been recently completed. In
thisstudy,patientswithdiﬀerentiatedthyroidcancerorMTC
received AMG-707 until disease progression or drug toxicity
occurred. Although the results of the MTC cohort have not
yet been reported, the results for the diﬀerentiated group
havebeenpresentedanddemonstratepartialtumorresponse
by Recist criteria in 12% of patients while another 70%
of patients demonstrated stable disease [28]. Clearly, these
studiesoﬀersigniﬁcantinsightintotheideathattargetingthe
soluble VEGF receptor may be a potential target for eﬀective
therapy in MTC.
4. SignalTransduction Proteins
4.1. Glycogen Synthase Kinase-3ß (GSK-3ß) in MTC. GSK-
3ß is a multifunctional serine/threonine protein kinase that
was ﬁrst described as playing a role in the regulation of
glycogen synthesis [29] and has since been shown to be
an important regulator of cell proliferation and survival.
In contrast to other kinases, GSK-3ß is highly active and
nonphosphorylated in unstimulated cells; however, activity
of the kinase is inhibited by phosphorylation of a single
serine residue (Ser9) in response to signaling cascades,
including the Raf-1/mitogen-regulated extracellular kinase
(MEK)/extracellular regulated kinase (ERK) signaling path-
way [29]. Recently, we have shown that Raf-1 activation in
humanMTCcellsresultsinphosphorylationandsubsequent
inactivation of GSK-3ß [30]; likewise, inactivation of GSK-
3ß by phosphorylation results in MTC growth inhibition
both in vitro and in vivo.
Severalsmallmoleculeinhibitors ofGSK-3ß areavailable
and demonstrate promising results both in vitro and in
vivo as potential targeted therapies for the treatment of
MTC. We have recently shown that inactivation of GSK-3ß
with lithium chloride (LiCl) and SB216763 results in MTC
diﬀerentiation and cell growth inhibition; likewise, these
small molecules have been shown to be associated with a
signiﬁcant decrease in NE markers such as human achaete-
scute complex-like l (ASCL1) and chromogranin A (CgA)
in cultured MTC cells [30]. In vivo studies in LiCl-treated
MTC xenograft mice demonstrated a signiﬁcant reduction
in tumor volume compared with those treated with control
[30].LiClhasbeenutilizedclinicallyformorethanﬁftyyears
as an adjunctive psychiatric medication for the treatment of
bipolar disorder and has shown only minimal adverse side
eﬀects. As such, the eﬃcacy of LiCl therapy in patients with
MTC is currently being investigated at our institution in
phase II clinical trials.
4.2.TheNotch1/Achaete-ScuteComplex-Like1(ASCL1)Path-
way. Notch1 is a multifunctional transmembrane receptor
that regulates cellular diﬀerentiation, proliferation, and
survival [31–33]. Binding of any one of the Notch ligands4 Journal of Oncology
(e.g., DLL-1 or JAG-1) promotes a sequence of proteolytic
cleavages resulting in the activated Notch intracellular
domain(NICD).ThisactivatedformofNotch1thentranslo-
catesto the nucleus and binds with the DNA-binding protein
complex CSL (C promoter-binding factor 1, suppressor of
hairless and Lag-1), resulting in transactivation of various
target genes like hairy enhancer of split-1 (HES-1).
Inhumancancercells,Notch1 actsaseitheratumorsup-
pressor or an oncogene. In many types of cancer, including
pancreatic, colon, nonsmall cell lung cancer (NSCLC), cervi-
calandrenalcellcancer,Notch1isupregulated;furthermore,
it has been suggested that expression of Notch1 signaling
prevents cellular diﬀerentiation and inhibits apoptosis in
these cancer types. Conversely, Notch1 signaling is very min-
imal or absent in NE tumors such as small-cell lung cancer
(SCLC), carcinoid cancer, and MTC [34]. In recent studies,
we have shown that activation of doxycycline-inducible
Notch1 in MTC cells signiﬁcantly reduced MTC cellular
growth and regulated calcitonin level in a dose-dependent
fashion; furthermore, these changes were dependent on the
amount of Notch1 protein [35]. These observations clearly
suggest that Notch1 signaling proteins are conserved in
MTC cells and support the idea that Notch1 activation
may be a potential target to treat patients with MTC
tumors.
Until recently, methods for the delivery of activated
Notch1 to tumor cells, aside from gene therapy, had been
nonexistent.Recently,wehavedemonstratedthatthehistone
deacetylase inhibitors valproic acid (VPA) and suberoyl bis-
hydroxamic acid (SBHA) act as strong Notch1 activators
in MTC cells [36, 37]. HDAC inhibitors represent a class
o fd i v e r s em o l e c u l e st h a tm o d u l a t eg e n et r a n s c r i p t i o nb y
increasing histone acetylation; the resulting alteration in
chromatin structure is believed to possess antineoplastic
eﬀects in preclinical and clinical studies in neuroblastoma
cells and a variety of other cancers [38]. In our studies,
SBHA and VPA treatment of MTC tumor cells resulted
in dose-dependent induction of the Notch1-intracellular
domain,theactiveformoftheprotein[36,37].Furthermore,
with Notch1 activation there was a concomitant decrease in
ASCL1 in vitro, a downstream target of Notch1 signaling.
Currently, we are seeking to develop phase II clinical trials
at our institution to determine the eﬃcacy of these HDAC
inhibitorsaspartofacomprehensivetherapyinpatientswith
MTC.
4.3. The Raf-1/Mitogen-Regulated Extracellular Kinase
(MEK)/Extracellular-Regulated Kinase (ERK) Signaling
Pathway. The Raf-1/MEK/ERK pathway has long been
recognized for its role in tumor biology and speciﬁcally
for its role in MTC tumor development [11]. Utilizing
an estradiol-inducible estrogen receptor fused with the
catalytic domain of the Raf-1 fusion protein, we have shown
that activation of the Raf-1 pathway is associated with a
reduction in NE hormones such as calcitonin and CgA
[39]. More importantly, ectopic raf-1 expression led to
signiﬁcant MTC growth suppression both in vitro and in
am o u s ex e n o g r a f tm o d e lo fM T C[ 40–43]. More recently,
Ning et al. [44] showed that the Raf-1 pathway regulates
essential cell-cell contact molecules and the metastatic
phenotype of MTC cells. These data clearly demonstrate
that although activation of the Raf-1 signaling pathway is
growth promoting in several cancers, in certain cell-speciﬁc
subtypes, Raf-1 activation inhibits tumorigenesis.
Despite the fact that methods to deliver activated Raf-
1 to MTC cells are limited, pharmacologic activators of the
Raf-1 pathway are currently under investigation. ZM336372,
originally identiﬁed as a potent and speciﬁc inhibitor of Raf
isoforms [45], has been shown to paradoxically demonstrate
a >100-fold induction of Raf-1 activity in NE cell culture
systems [45, 46]. In MTC cells in vitro, Kunnimalaiyaan
et al. [47] have demonstrated that ZM336372 treatment
resulted in increasing Raf-1 activation as measured by
phosphorylation of ERK1/2. Importantly, treatment with
ZM336372 in the presence of small interfering RNA against
Raf-1 resulted in an increase in Raf-1 production, suggesting
thatZM336372upregulatesRaf-1atthetranscriptionallevel.
While this is the ﬁrst description of a novel compound
capable of regulation the Raf-1 pathway in vitro, further
studies into the in vivo eﬀects of ZM336372 are ongoing.
5. Tumor Suppressor Genes and
Nuclear Oncogenes
5.1. The p53 Tumor Suppressor Genes. It is believed that
nearly50%ofallhumanmalignanciesareduetoinactivating
mutations of the p53 tumor suppressor gene; however, the
signiﬁcance of the p53 gene in MTC carcinogenesis is less
clear [48]. In a cohort of nearly 100 patients, Saltman et al.
clearlydemonstratedthepresenceofaberrantp53expression
in more aggressive phenotypes of thyroid carcinoma; the
study demonstrated a gradual increase in p53 immunopos-
itivity rate along the spectrum of thyroid carcinoma pro-
gression with a statistically signiﬁcant diﬀerence between
well-diﬀerentiated and anaplastic phenotypes (0% versus
31.8%, resp.; P<. 001) [49]. Similarly, using microdissection
and genotyping, Sheikh et al. studied 11 cases of MTC
for allelic losses in a panel of known tumor suppressor
genes in an attempt to elucidate the molecular basis for
clinical outcome. Among the tumor suppressor genes with
the most frequent allelic losses, p53 demonstrated a 44%
frequency of allelic loss. When combined with high-risk
clinicalvariables,includingadvancedpatientageandcervical
lymph node status, this genotype accurately predicted nearly
all patients in whom recurrence was likely [50]. Although
frequency of allelic loss in tumor suppressor genes like p53
may provide a useful adjunctive prognostic test in MTC,
there are currently no pharmacologic methods of selectively
targeting this genotype.
5.2.Thec-myc,c-jun,andc-fosNuclearProto-Oncogenes. The
proto-oncogenes c-myc, c-jun,a n dc-fos regulate the pro-
duction of nuclear transcription factors which activate the
expression of target genes involved in the control of thyroid
cell growth and diﬀerentiation [51]. Although no evidence
for gene rearrangements or ampliﬁcation of the nuclear
proto-oncogenes has been noted in thyroid carcinomas, inJournal of Oncology 5
human MTC samples, both a high frequency of c-myc allelic
losses [50] and elevated levels of c-myc and c-jun mRNA
havebeendemonstrated[52].Correlationbetweenthec-myc
transcript levels and the thyroid carcinoma diﬀerentiation
was reported, demonstrating that the less diﬀerentiated
tumors are associated with a greater abundance of c-myc
mRNA [53].
6. Conclusions
Although current treatment options for patients with
metastatic and refractory MTC are limited, recent advances
in molecular oncology have fostered the development
of novel small molecules which target speciﬁc pathways
that are thought to be essential in MTC tumorigenesis.
Inhibitors of the activated RET proto-oncogene and other
RTK inhibitors appear particularly promising, based on
the high prevalence of mutated oncogenes and speciﬁc
expression patterns in MTC [2]. Likewise, targeting angio-
genesis in MTC with small-molecule VEGF inhibitors and
multitarget kinase inhibitors is currently under investigation
and has demonstrated promising results. Many of these
newer RTK inhibitors are currently under investigation in
a series of randomized trials. Furthermore, alterations in
various cellular signaling pathways like the Notch1 and Raf-
1/MEK/ERK pathways oﬀer potential targets for novel small
molecule regulators. As molecular techniques continue to
be developed and the human genome sequenced, other
targettherapieswillundoubtedlybedevelopedandwillenter
the clinical setting, prompting patients with metastatic and
refractory MTC to participate in clinical trials evaluating
these novel therapies.
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